Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics

Trial Profile

Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Aflibercept (Primary) ; Bevacizumab (Primary) ; Ranibizumab (Primary)
  • Indications Retinal disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Sep 2017 Planned End Date changed from 1 Dec 2015 to 1 Mar 2018.
    • 12 Sep 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Feb 2018.
    • 18 Feb 2014 According to ClinicalTrials.gov record, planned end date changed from 1 Dec 2014 to 1 Dec 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top